Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model

• Published in: Journal of medicinal chemistry 2023-07, Vol.66 (13), p.8975-8992
• Main Authors: Salah, Mohamed, Tahoun, Mariam, Rudzitis-Auth, Jeannette, Stotz, Lisa, van Koppen, Chris J., Laschke, Matthias W., Abdelsamie, Ahmed S., Frotscher, Martin
• Format: Article
• Language: English
• Subjects: 17-Hydroxysteroid Dehydrogenases; Animals; Endometriosis - drug therapy; Enzyme Inhibitors - metabolism; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Estrogens - metabolism; Female; HEK293 Cells; Humans; Mice; Steryl-Sulfatase
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.3c00571

Treating estrogen-dependent diseases like endometriosis with drugs suppressing local estrogen activation may be superior to existing endocrine therapies. Steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) are key enzymes of local estrogen activation. We describe the rational design, synthesis, and biological profilation of furan-based compounds as a novel class of dual STS/17β-HSD1 inhibitors (DSHIs). In T47D cells, compound 5 showed irreversible inhibition of STS and potent, reversible inhibition of 17β-HSD1. It was selective over 17β-HSD2 and displayed high metabolic stabilities in human and mouse liver S9 fractions. No effect on cell viability was detected up to 31 μM (HEK293) and 23 μM (HepG2), respectively, and there was no activation of the aryl hydrocarbon receptor (AhR) up to 3.16 μM. Single daily application to mice revealed steady-state plasma levels high enough to make this compound eligible for an in vivo proof-of-principle study in a mouse endometriosis model.